|
|
||||||||
CUTTING EDGE |





* Laboratory of Immunology, First Medical Clinic, University of Mainz, Mainz, Germany;
Institute of Pathology, University of Lausanne, Lausanne, Switzerland; and
Regeneron Pharmaceuticals, Tarrytown, NY 10591
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
-producing TH1 cells, whereas IL-23 mediates TH1 effector functions (8, 9). | Materials and Methods |
|---|
|
|
|---|
Clones were derived from a mouse bacterial artificial chromosome library as described previously (10). IL-23 p19-deficient C57BL6 x 129 F1 embryonic stem cell clones were then injected into C57BL6/J blastocysts to generate chimeric mice. Male chimeras were then mated with female C57BL6/J mice to generate F1 breeders. Mice were back-crossed to C57BL6 and genotyped by PCR. The strain has been formally denoted B6;129-IL23tm1Gdy.
Induction of colitis and mouse endoscopy
Inducible mouse models for colitis were used as described previously (3, 11). In brief, colitis was induced by either giving mice 2.5% dextran sodium sulfate (DSS)3 in drinking water for 1 wk or by intrarectal administration of 0.5% TNBS. For continuous monitoring of colitis, the Coloview high-resolution mouse video endoscopic system (Karl Storz) was used. Colitis in Rag1 knockout mice was induced as described previously (12).
Isolation and culture of primary cells
Mouse bone marrow-derived dendritic cells (BMDCs) were generated as described previously (13). In brief, BM cells were isolated from the femurs of 6- to 10-wk-old mice and cultured in serum-free X-Vivo-15 medium (Cambrex) supplemented with 10 ng/ml murine GM-CSF (PeproTech). DCs were then purified using immunomagnetic beads specific for CD11c (Miltenyi Biotec). Intestinal lamina propria mononuclear cells (LPMCs) were isolated as described previously (3). For activation of cells the following reagents were used: 1 µg/ml bacterial LPS (Sigma-Aldrich), 1 µM CpG (MWG-Biotech), lipoteichoic acid (Sigma-Aldrich), double-stranded RNA (MWG-Biotech), and 5 ng/ml mouse IL-23 (R&D Systems).
Isolation of mRNA and RT-PCR
Total RNA was isolated using the RNA micro kit (Qiagen). Generation of cDNA was performed with Stratascript II reverse transcriptase (Invitrogen Life Technologies). Real-time quantitative PCR was performed on the iQ iCycler (Bio-Rad). For detection of IL-23 p19, IL-12 p40, IL-12 p35, and
-actin, mRNA-specific cDNA primers and fluorescent-labeled probes (Quantitect; Qiagen) were used. PCR was performed with the qRT-PCR Mix (Abgene).
ELISA
To measure IL-12 and IL-6 protein production, 106 BMDCs per well were seeded out in 1 ml of culture medium. After 48 h, cell-free culture supernatants were removed and assayed for IL-12 p70 and IL-6 concentration by specific ELISA (14).
Immunohistochemistry and
-galactosidase (
-gal) assay
Immunofluorescence of cryosections was performed using the TSA Cy3 system (PerkinElmer) and a fluorescence microscope (Olympus) as described (14). In brief, cryosections were fixed in paraformaldehyde and incubated overnight with primary Abs specific for either CD11c (Santa Cruz Biotechnology) or IL-23 p19 (polyclonal rabbit anti-mouse peptide Ab; Eurogentec). Subsequently, the slides were incubated with biotinylated secondary Abs (Dianova), streptavidine-HRP, and finally, with tyramide (Cy3 or FITC) according to the manufacturers instructions (PerkinElmer). Nuclei were counterstained with Hoechst 3342 (Molecular Probes).
Statistical analysis
Endoscopic data were analyzed by Students t test using the program Excel (Microsoft)
| Results and Discussion |
|---|
|
|
|---|
Proinflammatory cytokines produced by APCs play a major role in chronic intestinal inflammation (15, 16), although the precise role of IL-23 in this context remains to be determined. However, constitutive expression of IL-23 and p40 in DCs of the terminal ileum was recently observed in healthy mice (14). Such expression of p40 was stimulated by bacterial uptake in DCs with subsequent induction of p40 via NF-
B. To investigate whether bacteria-induced IL-23 p19 is expressed in the colonic lamina propria of mice suffering from experimental Th1-mediated colitis, we performed immunohistochemistry using Abs against p19. Colitis was induced by the adoptive transfer of CD4+CD62L+ T cells into immunocompromised Rag1 knockout mice. Although no p19 was detectable in the colons of healthy unreconstituted animals, a specific cytoplasmic staining was seen in lamina propria cells of mice with experimental colitis (data not shown). These data suggested a role of IL-23 in the pathogenesis of colitis, and we further addressed this point using p19-deficient mice.
Previous studies have shown that mice deficient for IL-23 were protected from a variety of experimental animal models known to be driven by pathogenic T cell populations (8, 9). To investigate whether IL-23 plays an active role in the pathogenesis of colitis, we next created mice with a targeted deletion of the endogenous IL-23 p19 gene. Hereby, the endogenous gene was replaced by an in-frame insertion of the reporter gene LacZ with nucleotide precision (Fig. 1A), thereby allowing analysis of the activity of the endogenous IL-23 p19 promoter in the resulting knockin mice. IL-23 p19-deficient mice did not produce any detectable p19 mRNA in the gut (Fig. 1B) and elsewhere in the body (data not shown). However,
-gal was induced by BMDCs upon stimulation with TLR ligands, implicating that lacZ reporter gene activity was properly regulated by the endogenous IL-23 p19 promoter (data not shown). To investigate whether IL-23 p19 develop colitis, we next performed experiments with p19-deficient mice and wild-type littermates in the DSS model of experimental colitis. Accordingly, p19-deficient, heterozygous, and wild-type (littermates) mice were given a low dose of DSS in drinking water. Although wild-type mice lost little weight during low-dose DSS treatment, knockout mice showed a constant decline of their body weight starting at day 3 after DSS treatment (Fig. 1C). Furthermore, knockout mice did not recover even after withdrawal of DSS, indicating a chronic state of colitis in these mice. Heterozygous mice also lost body weight, but to a lesser extent, compared with knockout animals. To investigate whether the IL-23 p19 promoter is induced in mice suffering from colitis, we analyzed
-gal activity in colon lysates of heterozygous mice. Colitis-induced weight loss correlated well with the level of reporter gene activity detected in these mice (data not shown), implicating that IL-23 is induced during the course of colitis.
|
|
In summary, we demonstrate that in contrast to experimental models of arthritis and multiple sclerosis, IL-23 is not essential for the development of DSS colitis and TH1-mediated TNBS colitis. In fact, we found that IL-23 p19 knockout mice are highly susceptible for development of TH1-mediated colitis upon TNBS administration and had even more severe colitis than wild-type mice. Thus, our data implicate important differences between certain TH1-mediated mucosal immune response in the gut and TH1-mediated diseases in other organs.
IL-23 down-regulates IL-12 by inhibition of IL-12 p35 and p40 expression
To investigate the cause of aggravated colitis in mice deficient for IL-23, we next investigated cytokine production by BMDCs isolated from wild-type and p19-deficient mice. Because cytokines such as IL-6, TNF-
, and IL-12 play a major role in the pathogenesis of colitis, we measured expression of these cytokines in BMDC supernatants by ELISA (Fig. 3A). IL-6 and TNF-
were strongly induced by stimulation in both wild-type and IL-23 p19-deficient DCs, and no significant differences could be detected. In contrast, IL-12 heterodimer was detectable in the supernatant of LPS-stimulated p19-deficient, but not wild-type, DCs. In contrast, CpG stimulation led to IL-12 release in both wild-type and knockout DCs, although the level of IL-12 released by wild-type cells was lower, compared with p19-deficient cells. Thus, our data demonstrate an overexpression of IL-12 by DCs in the absence of IL-23. To confirm overexpression of IL-12 in the gut immune system of mice deficient for IL-23 p19, we next isolated LPMCs from wild-type and knockout animals and stimulated them with LPS. LPMCs lacking p19 produced IL-12 upon stimulation with LPS, whereas IL-12 levels in wild-type LPMCs were below the detection limit (Fig. 3B). Thus, LPMCs from IL-23 p19 knockout mice produced enhanced levels of IL-12.
|
Inhibition of IL-12 p40 rescues IL-23 p19-deficient mice from lethal colitis
To investigate whether overproduction of IL-12 could be responsible for the aggravated colitis seen in IL-23 p19-deficient mice, we neutralized IL-12 by using an IL-12 p40-neutralizing Ab. Accordingly, IL-23 p19 knockout mice were treated with TNBS and then separated into two groups (Fig. 4A). One group received 1 mg of neutralizing anti-IL-12 p40 Ab in PBS, whereas the second group was treated with PBS alone. The development of wasting disease was monitored throughout the course of the experiment. Mice treated with PBS alone developed wasting disease leading to the death of all animals by day 22 of the experiment (Fig. 4B). In contrast, IL-23 p19-deficient mice treated with two doses of anti-IL-12 p40 Abs (day 0 and day 7) were all rescued from lethal colitis. Accordingly, Ab-treated animals showed only a mild weight loss not leading to an irreversible and fatal wasting syndrome. In agreement with the weight analysis, endoscopy of mice treated with PBS showed signs of strong colitis characterized by a thickened mucosa, loss of the normal vessel pattern, and bleedings (Fig. 4C). In contrast, mice treated with IL-12 p40 Ab showed only very mild endoscopic signs of colitis. Thus, IL-12 emerges as a key player in the severe TNBS colitis seen in the absence of IL-23 p19.
|
IL-12 has been proposed as a key cytokine in the pathogenesis of TH1-mediated intestinal inflammation, because neutralizing IL-12 p40 Abs caused suppression of established experimental colitis in various animal models (2, 3, 4). Furthermore, transgenic mice for the IL-12 inducible transcription factor STAT-4 were highly susceptible to TH1-driven colitis (17, 18). These studies suggested the potential use of IL-12 inhibitors for therapy of Crohn's disease, because this disease is characterized by T-bet-expressing TH1 T lymphocytes in the gut. In fact, a recent phase 2 study reported significantly higher remission rates in anti-IL-12 Ab-treated patients, compared with controls (6). Thus, IL-12 may be a promising target for future therapeutic intervention in patients with Crohns disease. However, all of the above investigations were performed using Abs against the p40 subunit of IL-12 that neutralizes IL-12 and IL-23 simultaneously, and experimental colitis in IL-10-deficient mice is associated with increased IL-23 levels (19). Therefore, studies on the role of IL-23 deficiency in intestinal inflammation are required. In this study, we provide evidence that suppression of both cytokines is required for prevention of TH1-mediated TNBS colitis in the gut. Our data are consistent with a model in which overproduction of IL-12 p35/p40 in p19-deficient mice is the cause of aggravated TNBS colitis in these mice, compared with wild-type mice. Thus, although p35 and p40 subunits are not generally affected by the absence of IL-23 in all experimental systems (20), these findings demonstrate the existence of cross-regulation of IL-12 levels by IL-23 in the gut and demonstrate the in vivo relevance of such cross-regulation for TH1-mediated TNBS colitis. Our data thus support a model in which the production of IL-12 is regulated by other IL-12 family members, such as IL-23, during experimental colitis.
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 The work of M.F.N. was supported by the collaborative research grant SFB548. ![]()
2 Address correspondence and reprint requests to Dr. Markus F. Neurath, Laboratory of Immunology, I. Medical Clinic, University of Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany. E-mail address: neurath{at}1-med.klinik.uni-mainz.de ![]()
3 Abbreviations used in this paper: DSS, dextran sodium sulfate; BMDC, bone marrow dendritic cell; LPMC, lamina propria mononuclear cell; gal, galactosidase; MEICS, murine endoscopic index of colitis severity. ![]()
Received for publication February 6, 2006. Accepted for publication July 6, 2006.
| References |
|---|
|
|
|---|
, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161: 3143-3319.
expression by T cells. J. Exp. Med. 187: 1225-1234.
signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol. 173: 6526-6531.
induced Foxp3+ regulatory T cells suppress Th1-mediated experimental colitis. Gut 55: 671-680. 
activation. J. Immunol. 174: 2814-2824.
-producing CD4+ T cells that respond to bacterial antigens. J. Immunol. 162: 1884-1888.
responses if IL-12 p70 is available. J. Immunol. 2005. 175: 788-795. This article has been cited by other articles:
![]() |
S Brand Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease Gut, August 1, 2009; 58(8): 1152 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Lee, P. Wang, M. G. Kattah, S. Youssef, L. Steinman, K. DeFea, and D. S. Straus Differential Regulation of Chemokines by IL-17 in Colonic Epithelial Cells J. Immunol., November 1, 2008; 181(9): 6536 - 6545. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Bandyopadhyay, C. A. de la Motte, S. P. Kessler, V. C. Hascall, D. R. Hill, and S. A. Strong Hyaluronan-Mediated Leukocyte Adhesion and Dextran Sulfate Sodium-Induced Colitis Are Attenuated in the Absence of Signal Transducer and Activator of Transcription 1 Am. J. Pathol., November 1, 2008; 173(5): 1361 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yi, D. Zhao, C.-L. Lin, C. Zhang, Y. Chen, I. Todorov, T. LeBon, F. Kandeel, S. Forman, and D. Zeng Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease Blood, September 1, 2008; 112(5): 2101 - 2110. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Muhlbauer, P. M. Chilton, T. C. Mitchell, and C. Jobin Impaired Bcl3 Up-regulation Leads to Enhanced Lipopolysaccharide-induced Interleukin (IL)-23P19 Gene Expression in IL-10-/- Mice J. Biol. Chem., May 23, 2008; 283(21): 14182 - 14189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. H. Gaston Cytokines in arthritis the 'big numbers' move centre stage Rheumatology, January 1, 2008; 47(1): 8 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Smith, A. Zarbock, M. A. Stark, T. L. Burcin, A. C. Bruce, P. Foley, and K. Ley IL-23 Is Required for Neutrophil Homeostasis in Normal and Neutrophilic Mice J. Immunol., December 15, 2007; 179(12): 8274 - 8279. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizutani, T. Sakurai, T. Shibata, K. Uchida, J. Fujita, R. Kawashima, Y. I. Kawamura, N. Toyama-Sorimachi, T. Imai, and T. Dohi Dose-Dependent Differential Regulation of Cytokine Secretion from Macrophages by Fractalkine J. Immunol., December 1, 2007; 179(11): 7478 - 7487. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. McGovern and F. Powrie The IL23 axis plays a key role in the pathogenesis of IBD Gut, October 1, 2007; 56(10): 1333 - 1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Sheibanie, J.-H. Yen, T. Khayrullina, F. Emig, M. Zhang, R. Tuma, and D. Ganea The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23->IL-17 Axis J. Immunol., June 15, 2007; 178(12): 8138 - 8147. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Karrasch, J.-S. Kim, M. Muhlbauer, S. T. Magness, and C. Jobin Gnotobiotic IL-10-/-;NF-{kappa}BEGFP Mice Reveal the Critical Role of TLR/NF-{kappa}B Signaling in Commensal Bacteria-Induced Colitis J. Immunol., May 15, 2007; 178(10): 6522 - 6532. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fichtner-Feigl, I. J. Fuss, C. A. Young, T. Watanabe, E. K. Geissler, H.-J. Schlitt, A. Kitani, and W. Strober Induction of IL-13 Triggers TGF-beta1-Dependent Tissue Fibrosis in Chronic 2,4,6-Trinitrobenzene Sulfonic Acid Colitis J. Immunol., May 1, 2007; 178(9): 5859 - 5870. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Duerr, K. D. Taylor, S. R. Brant, J. D. Rioux, M. S. Silverberg, M. J. Daly, A. H. Steinhart, C. Abraham, M. Regueiro, A. Griffiths, et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene Science, December 1, 2006; 314(5804): 1461 - 1463. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |